First report of staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: Evidence of in vivo cfr mobilization

Journal of Clinical Microbiology

Volumn 48, Issue 8, 2010, Pages 3041-3043

  Mendes, Rodrigo E ^a   Deshpande, Lalitagauri ^a   Rodriguez Noriega, Eduardo ^b   Ross, James E ^a   Jones, Ronald N ^a   Morfin Otero, Rayo ^c  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; OXAZOLIDINONE DERIVATIVE; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIAL RNA; RNA 23S;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; HUMAN; IN VIVO STUDY; LETTER; MEXICO; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS COHNII; STAPHYLOCOCCUS EPIDERMIDIS; ADULT; CASE REPORT; DRUG EFFECTS; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MEXICO; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXAZOLIDINONES; RNA, BACTERIAL; RNA, RIBOSOMAL, 23S; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 77955433744     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00880-10     Document Type: Letter

References (20)

1. Clinical and Laboratory Standards Institute. 2009. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Clinical and Laboratory Standards Institute. 2010. M100-S20. Performance standards for antimicrobial susceptibility testing, 20th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Devulder, G., G. Perriere, F. Baty, and J. P. Flandrois. 2003. BIBI, a bioinformatics bacterial identification tool. J. Clin. Microbiol. 41:1785-1787.
4. Farrell, D. J., R. E. Mendes, J. E. Ross, and R. N. Jones. 2009. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn. Microbiol. Infect. Dis. 65:392-403.
5. Huebner, J., and D. A. Goldmann. 1999. Coagulase-negative staphylococci: role as pathogens. Annu. Rev. Med. 50:223-236.
6. Jones, R. N., J. E. Ross, J. M. Bell, U. Utsuki, I. Fumiaki, I. Kobayashi, and J. D. Turnidge. 2009. Zyvox annual appraisal of potency and spectrum program: linezolid surveillance program results for 2008. Diagn. Microbiol. Infect. Dis. 65:404-413.
7. Kehrenberg, C., F. M. Aarestrup, and S. Schwarz. 2007. IS21-558 insertion sequences are involved in the mobility of the multiresistance gene cfr. Antimicrob. Agents Chemother. 51:483-487.
8. Locke, J. B., M. Hilgers, and K. J. Shaw. 2009. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob. Agents Chemother. 53:5265-5274.
9. Locke, J. B., M. Hilgers, and K. J. Shaw. 2009. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob. Agents Chemother. 53:5275-5278.
10. Long, K. S., J. Poehlsgaard, C. Kehrenberg, S. Schwarz, and B. Vester. 2006. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50:2500-2505.
11. McDougal, L. K., C. D. Steward, G. E. Killgore, J. M. Chaitram, S. K. McAllister, and F. C. Tenover. 2003. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120.
12. Mendes, R. E., L. M. Deshpande, M. Castanheira, J. DiPersio, M. A. Saubolle, and R. N. Jones. 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-2246.
13. Miller, K., C. J. Dunsmore, C. W. Fishwick, and I. Chopra. 2008. Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center. Antimicrob. Agents Chemother. 52:1737-1742.
14. Miragaia, M., J. C. Thomas, I. Couto, M. C. Enright, and H. de Lencastre. 2007. Inferring a population structure for Staphylococcus epidermidis from multilocus sequence typing data. J. Bacteriol. 189:2540-2552. (Pubitemid 46411368)
15. Morales, G., J. J. Picazo, E. Baos, F. J. Candel, A. Arribi, B. Peláez, R. Andrade, M. A. de la Torre, J. Fereres, and M. Sánchez-García. 2010. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 50: 821-825.
16. Piette, A., and G. Verschraegen. 2009. Role of coagulase-negative staphylococci in human disease. Vet. Microbiol. 134:45-54.
17. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
18. Toh, S. M., L. Xiong, C. A. Arias, M. V. Villegas, K. Lolans, J. Quinn, and A. S. Mankin. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64:1506-1514.
19. Traczewski, M. M., and S. D. Brown. 2008. Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent. Antimicrob. Agents Chemother. 52: 3863-3867.
20. Wong, A., S. P. Reddy, D. S. Smyth, M. E. Aguero-Rosenfeld, G. Sakoulas, and D. A. Robinson. 2010. Polyphyletic emergence of linezolid-resistant staphylococci in the United States. Antimicrob. Agents Chemother. 54:742-748.